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Abstract
Activating mutations in the receptor tyrosine kinase KIT, most notably KIT D816V, are 
commonly observed in patients with systemic mastocytosis. Thus, inhibition of KIT has been a 
major focus for treatment of this disorder. Here we investigated a novel approach to such 
inhibition. Utilizing rational drug design, we targeted the switch pocket (SP) of KIT which 
regulates its catalytic conformation. Two SP inhibitors thus identified, DP-2976 and DP-4851, 
were examined for effects on neoplastic mast cell proliferation and mast cell activation. 
Autophosphorylation of both wild type (WT) and, where also examined, KIT D816V was blocked 
by these compounds in transfected 293T cells, HMC 1.1 and 1.2 human mast cell lines; and in 
CD34+-derived human mast cells activated by stem cell factor (SCF). Both inhibitors induced 
apoptosis in the neoplastic mast cell lines and reduced survival of primary bone marrow mast cells 
from patients with mastocytosis. Moreover, the SP inhibitors more selectively blocked SCF 
potentiation of FcεRI-mediated degranulation. Overall, SP inhibitors represent an innovative 
mechanism of KIT inhibition whose dual suppression of KIT D816V neoplastic mast cell 
proliferation and SCF enhanced mast cell activation may provide significant therapeutic benefits.
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Introduction
KIT is a member of the tyrosine kinase-containing family of growth factor receptors which 
is expressed on restricted hematopoietic cell lineages including mast cells.(1) Activation of 
KIT, following ligation by stem cell factor (SCF), is critical for mast cell growth, survival, 
differentiation and homeostasis and may contribute to mast cell homing to resident tissues.
(2) The extent of antigen-mediated mast cell activation within these tissues also has the 
capacity to be up regulated by SCF-dependent KIT activation.(3) Hence inappropriate KIT 
activation profoundly influences mast cell-driven pathology.
Systemic mastocytosis is characterized by the pathologic accumulation of neoplastic mast 
cells in various tissues accompanied by activating mutations in KIT, most notably the 
aspartic acid to valine substitution at residue 816 (KIT D816V).(4) Clinically, this clonal 
accumulation often results in persistent mast cell mediator-related symptoms and, in rare 
cases, aggressive neoplastic overgrowth with end organ failure. In these latter presentations, 
lifespan is significantly reduced and cytoreductive therapy is required.(5) To date, tyrosine 
kinase inhibitors targeting the KIT D816V mutation have demonstrated only modest 
efficacy in advanced disease states and are often accompanied by significant side effects, 
likely the result of off-target kinase inhibition.(6–9)
Most tyrosine kinase inhibitors target the ATP binding pocket which is often conserved 
amongst kinases and subject to competition from high intracellular ATP concentrations. For 
reasons not clearly understood, certain ATP competitive inhibitors do not potently inhibit 
oncogenic forms of kinases which adopt aggressive, constitutively active conformations 
independent of normal regulatory mechanisms. KIT kinase can be aggressively activated in 
this manner and KIT mutants show unique mechanisms of drug resistance to imatinib and 
sunitinib in gastrointestinal stromal tumor patients.(10)
KIT has an interior pocket located between the N- and C-lobes of the kinase which functions 
as a switch pocket (SP). KIT also has two pendent switch ligands which compete for 
occupancy of this SP.(11) If the inhibitory switch (exon 11 juxtamembrane domain) of KIT 
occupies this SP, the kinase adopts an inactive conformation. If the activating switch (exon 
17 activation loop) occupies this SP, the kinase adopts a catalytically active conformation. 
Thus, changes in phosphorylation of both the inhibitory and activating switches govern the 
overall activity of KIT by regulation of the occupancy of its SP by its pendent inhibitory and 
activating switches.
Primary mutations and/or deletions in the exon 11 inhibitory switch render KIT 
constitutively active and such mutations drive the progression of gastrointestinal stromal 
tumors (GIST).(12) In mast cell leukemia/mastocytosis, the primary KIT mutation resides in 
the activating switch, and in particular, the D816V exon 17 mutation is most aggressive. 
Classical ATP competitive KIT inhibitors, including imatinib, sunitinib, sorafenib, 
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regorafenib, do not block this aggressive mutant form of KIT. The SP inhibitors, DP-2976 
and DP-4851, were developed by rational design to block access to the KIT SP and prevent 
KIT D816V from adopting the catalytically active conformation. Additionally, because SP 
inhibitors are not ATP competitive, they are resilient even to high 4–5 mM concentrations of 
cellular ATP.
Here we describe the ability of two KIT SP inhibitors, DP-2976 and DP-4851, to potently 
and selectively inhibit both wild type (WT) and KIT D816V activation and consequently 
proliferation of both neoplastic and non-neoplastic mast cell populations. Furthermore, these 
inhibitors effectively blocked the ability of SCF to enhance antigen-mediated mast cell 
activation. These studies demonstrate that by targeting the switch pocket, this class of KIT 
inhibitors possesses a novel mechanism of inhibition whose dual suppression of KIT D816V 
neoplastic proliferation and SCF enhanced mast cell activation advocate future clinical 
development.
Patients, Materials and Methods
Reagents and antibodies
DP-2976 and DP-4851 were synthesized within Deciphera Pharmaceuticals LLC (Lawrence, 
KS, USA). PKC 412 and imatinib were purchased from LC laboratories (Woburn, MA, 
USA). All compounds were prepared and stored as a 10 mM stock solution in DMSO at 
−20°C. The following antibodies were used for immunoblotting: mouse anti human KIT 
(Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti pKit (Tyr-823) (Invitrogen, 
Carlsbad, CA), anti β– actin monoclonal antibody (Sigma-Aldrich, St. Louis, MO), 
horseradish peroxidase-conjugated anti-mouse (Sigma-Aldrich, St. Louis, MO) and anti-
rabbit IgG (Amersham Biosciences, Piscataway, NJ).
In vitro kinase assays
KIT catalytic activity was determined by following the production of ADP from the kinase 
reaction through coupling with the pyruvate kinase/lactate dehydrogenase system.(13) The 
reaction mixture (100 µl) contained KIT (KIT residues T544-V976, 6 nM), polyE4Y (1 mg/
ml), MgCl2 (10 mM), pyruvate kinase (~ 3 units), lactate dehydrogenase (~ 4 units), 
phosphoenol pyruvate (1 mM), and NADH (0.28 mM) in 90 mM Tris buffer containing 0.2 
% octyl-glucoside and 1% DMSO, pH 7.5. Test compounds were incubated with KIT and 
other reaction reagents at 30 °C for 30 min before ATP (0.2, 1.2 or 4 mM) was added to start 
the reaction. The absorption at 340 nm was monitored continuously for 1 h at 30°C. Percent 
inhibition was obtained by comparison of reaction rate with that of a control (i.e. with no 
test compound).
Cell culture
The HMC 1.1 and HMC 1.2 neoplastic mast cell lines were cultured as described.(14) Both 
cell lines carry an activating KIT V560G mutation (loss-of-function mutation in the exon 11 
inhibitory switch). In addition, the HMC 1.2 cell line harbors the KIT D816V mutation 
(gain-of-function mutation in the exon 17 activating switch). The 293T cell line was 
cultured in Iscove’s DMEM containing 10% fetal bovine serum, 2 mM L-glutamine, 100 
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U/ml penicillin and 100 µg/ml streptomycin (Mediatech, Manassas VA). Human mast cells 
(HuMCs) derived from CD34+ pluripotent blood progenitor cells were cultured as described.
(15)
Cell transfections
pcDNA3-KIT (GNNK+ variant(16)) was a kind gift from Gunnar Nilsson (Karolinska 
Institutet, Stockholm, Sweden). The KIT D816V mutation was created using the 
QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the 
manufacturer’s instructions. KIT and KIT D816V open reading frames were cloned into the 
pcDNA3.1 expression vector (Invitrogen, Carlsbad, CA) using standard molecular biology 
techniques.(17) These vectors were transfected into 293T cells using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. All transfections were carried out 
in DMEM medium containing 10% fetal bovine serum and 2 mM L-Glutamine. Three 
hundred thousand cells were plated in 6 well plates in 2 ml medium, and cultured overnight. 
The next day, the medium was replaced with 1 ml of fresh medium to which 1 µg of DNA 
and 5 µl of lipofectamine in 100 µl of Opti-MEM (Invitrogen, Carlsbad, CA) were added. 
Inhibitors (1 – 1000 nM in a final concentration of 0.1% DMSO) were added to the 
indicated wells. After 24 h, cells were washed twice in PBS and lysed using 100 µl of RIPA 
buffer (Thermo Fisher, Pittsburgh, PA). The protein concentrations were measured using 
Bradford assay (Bio Rad, Hercules, CA) and 20 µg of protein were used for immunoblot 
analysis as described.(18) Immunoreactive proteins were visualized with enhanced 
chemiluminesence (ECL) (Perkin Elmer Life Sciences, Waltham, MA) and the density of 
the appropriate bands was determined to quantitate the changes in phosphorylation.
Cell proliferation assay
HMC 1.1 and HMC 1.2 cells were plated at 5×104 cells/mL with the inhibitors (1 – 1000 
nM) in a final concentration of 0.1% DMSO. After 72 h, an equal volume of 2X CyQuant 
direct detection reagent (Invitrogen) was added into the cells in culture. Following a 1 h 
incubation at 37°C with detection reagent, sample fluorescence was detected by using 
492/535 nm wavelengths filter sets.
Apoptosis assay
HMC 1.1 and HMC 1.2 cells were plated at 1×105 cells/mL with 1000 nM of the inhibitors 
in DMSO (final concentration 0.1%). At 24, 48 and 72 h, annexin V staining using the 
Annexin V-FITC Apoptosis Detection Kit from BioVision (Mountain View, CA) was 
performed according to the manufacturer’s instructions. The samples were analyzed using a 
FACSCalibur (BD Biosciences, San Jose, CA) flow cytometer equipped with Cellquest (BD 
Biosciences) software.
Human mast cell degranulation assay
HuMCs were sensitized overnight with biotinylated-human IgE (100 ng/ml) in cytokine-free 
medium and rinsed with HEPES buffer (10 mM HEPES pH7.4, 137 mM NaCl, 27 mM KCl, 
0.4 mM Na2HPO4.7H2O, 5.6 mM glucose, 1.8 mM CaCl22H2O, 1.3 mM MgSO4.7H2O) 
containing 0.04% bovine serum albumin.(19) Five thousand cells per well were plated in 96 
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well plates and preincubated in the presence and absence of inhibitors for 90 min at 37°C. 
The cells were then triggered with either 1 ng/ml streptavidin or 0.1 ng/ml streptavidin in the 
presence or absence of 10 ng/ml SCF. After 30 min, β–hexosaminidase (β-hex) activity in 
the supernatants and remaining cells was determined and degranulation was determined as 
the percentage of the total β-hex recovered from the supernatants.(20)
KIT phosphorylation
HuMCs were incubated overnight in growth medium without SCF and then washed 3 times 
in HEPES buffer containing 0.04% BSA. One million cells in 100 µl of HEPES buffer 
containing 0.04% BSA were pre-incubated with or without the inhibitors (1 – 1000 nM in 
0.1% DMSO) for 90 min at 37°C and then the cells were incubated with 10 ng/ml SCF for 2 
min. Cell lysates were prepared and 20 µl aliquots were loaded on to 4 – 12% NuPAGE Bis-
Tris gels for electrophoretic separation and immunoblotting as described.(18) 
Immunoreactive proteins were visualized with enhanced chemiluminesence ECL (Perkin 
Elmer Life Sciences, Waltham, MA) and the density of the appropriate bands was 
determined to quantitate the changes in phosphorylation.
HMC 1.1 and HMC 1.2 cells were incubated for 3 h in Iscove’s DMEM media without FBS 
and then washed 3 times in HEPES buffer. Three hundred thousand cells in 100 µl of 
HEPES buffer containing 0.04% BSA were incubated with/without the inhibitors (1 – 1000 
nM in 0.1% DMSO) for 90 min at 37°C. Cell lysate preparation and immunoblotting was 
performed in the same manner as above.
Patient samples and ex vivo mast cell experiments
Six patients with systemic mastocytosis were evaluated at the NIH between 2010 and 2011 
as part of an Institutional Review Board-approved research protocol designed to study the 
pathogenesis and natural history of systemic mastocytosis (NCT00044122). All patients 
were diagnosed according to the World Health Organization (WHO) criteria.(5) The 
presence of the KIT D816V mutation was determined by PCR/RFLP as described.(21) 
Following informed consent, bone marrow mononuclear cells were isolated and incubated 
with the inhibitors (100, 1000 nM, 0.1% DMSO) for 7 d in the presence of SCF (100 ng/ml). 
Mast cell numbers were assessed by flow cytometry and normalized to numbers in the 
absence of inhibitor.(22)
Statistical analysis
Statistical analysis was performed using PRISM software, version 5 (GraphPad). Data were 
analyzed by a two tailed Student’s t test. The levels of significance were as follows: *, 
p<0.05; **, p<0.005; ***, p<0.0005. IC50 values were calculated using a nonlinear 
regression (curve fit)--sigmoidal dose-response equation.
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DP-2976 and DP-4851 selectively inhibit WT and mutant KIT kinase activity at nanomolar 
concentrations
As part of drug discovery efforts, DP-2976 and DP-4851 were optimized for their inhibitory 
activity in KIT kinase assays. Low nanomolar IC50 values were observed in WT and 
mutated forms of KIT, including KIT D816V (Figure 1A). The inhibitory potencies were 
unaffected by increases in ATP concentrations up to 4 mM (Figure 1B), demonstrating that 
the ATP binding pocket was not targeted.
DP-2976 and DP-4851 inhibit intracellular KIT phosphorylation
To explore the effects of the SP inhibitors on intracellular KIT activity, WT KIT and KIT 
D816V were expressed in 293T cells and the autophosphorylation status was assessed. Both 
DP-2976 and DP-4851 decreased the autophosphorylation of both wild type and KIT 
D816V in a concentration-dependent manner (Figure 2).
The effect of the inhibitors on KIT phosphorylation was also examined in the HMC 1.1 
(negative for D816V mutation) and HMC 1.2 (positive for D816V mutation) neoplastic 
human mast cell lines. DP-2976 and DP-4851 inhibited KIT phosphorylation in a dose 
dependent manner. Furthermore, these compounds appeared more potent than PKC 412 in 
this model (Figure 3).
DP-2976 and DP-4851 inhibit growth and induce apoptosis in HMC-1.1 and HMC1.2 mast 
cell lines at nanomolar concentrations
We next assessed the anti-neoplastic activity of the SP inhibitors in HMC 1.1 and HMC 1.2 
cell proliferation assays. Both DP-2976 and DP-4851 potently inhibited HMC 1.1 
proliferation with IC50 values of 2 nM and 4 nM respectively. These values were lower than 
that of imatinib (10 nM) or PKC 412 (135 nM) (Figure 4A). Similarly, when evaluated in 
HMC 1.2 cells bearing the KIT D816V mutation, both DP-2976 and DP-4851 inhibited cell 
proliferation with IC50 values of 50 nM and 117 nM respectively. Similar to previous 
reports, imatinib demonstrated no activity and PKC 412 demonstrated an IC50 of 138 nM 
(Figure 4B).(23)
The HMC 1.1 and HMC 1.2 cells were then treated with the inhibitors (1000 nM) and 
evaluated for apoptosis over 72 h. A time dependent increase in apoptosis was induced by 
the SP inhibitors in both cell lines, with over 60% of the cells annexin-V positive at the 72 h 
(Figures 4C and 4D). Together, the SP inhibitors exhibited potent anti-neoplastic activity via 
apoptosis and outperformed current ATP competitive inhibitors in this system.
DP-2976 and DP-4851 inhibit survival of KIT D816V+ primary bone marrow mast cells
To determine if the in vitro observations translate clinically, we examined the efficacy of the 
SP inhibitors on neoplastic mast cells of patients with systemic mastocytosis. Patient 
characteristics are presented in Table 1. Patient #1 lacked the KIT D816V mutation and mast 
cells from this patient exhibited a dose dependent decrease in survival in response to the SP 
inhibitors (Figure 5A). Furthermore, DP-2976 (1 µM) produced a 78% reduction (p<0.0005) 
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and DP-4851 a 63% reduction (p<0.005) in the viability of mast cells collected from the 
bone marrow of KIT D816V-positive systemic mastocytosis patients (n=5) (Figure 5B). A 
comparable level of reduction (88%) was seen with PKC 412 at 1000 nM (p<0.0005). No 
statistical difference in inhibition profiles was observed in the absence of SCF (data not 
shown). These results support that targeting the KIT switch pocket offers an innovative 
mechanism of inhibition with potential clinical application.
DP-2976 and DP-4851 suppress KIT phosphorylation in primary human mast cells
We next examined the effects of the inhibitors on WT KIT signaling in non-neoplastic 
HuMCs derived from peripheral blood progenitors, in response to SCF (10 ng/ml). In 
agreement with the transfection experiments (see figure 2), both DP-2976 and DP-4851 
inhibited KIT phosphorylation in a concentration-dependent manner (Figure 6).
DP-2976 and DP-4851 inhibit SCF-enhanced mast cell activation
In addition to the end organ damage induced by neoplastic mast cell proliferation, patients 
with systemic mastocytosis suffer from mast cell activation and mediator-related symptoms. 
Enhanced mast cell degranulation via KIT activation is well described and targeting such 
may provide therapeutic benefit. With this in mind we evaluated the SP inhibitors for their 
effect on SCF enhanced mast cell degranulation. DP-2976, DP-4851 and imatinib had 
minimal effects on FcεRI mediated mast cell degranulation (Figure 7, open circles), with 
inhibition observed only at the highest concentration (1000 nM). SCF-enhanced 
degranulation (Figure 7, solid circles) was evaluated in tandem and as previously observed, 
imatinib inhibited SCF-enhanced degranulation at the highest concentration (1000 nM).(19) 
Additionally, both DP-2976 and DP-4851 also suppressed SCF-enhanced degranulation in a 
concentration-dependent manner with IC50 values of 18 nM and 27 nM respectively. In 
contrast, in addition to blocking SCF-enhanced degranulation (IC50=7nM), PKC 412 
potently inhibited FcεRI-mediated degranulation (IC50=21nM). A similar reported 
observation suggested this to be the result of the inherent multi-kinase inhibition profile of 
PKC 412.(24)
Discussion
Targeting kinase control switch pockets appears a promising approach to effectively inhibit 
oncogenic kinase activity. Recently, DCC-2036 was identified as a switch pocket inhibitor 
of ABL kinase.(25, 26) The gatekeeper mutant T315I represents an escape mutant of ABL 
and the oncogenic fusion protein BCR-ABL T315I is not readily controlled by currently 
marketed therapies.(27) DCC-2036 potently blocks ABL T315I, signifying that SP 
inhibitors may hold promise to suppress other kinases harboring oncogenic mutations. 
Indeed, this study demonstrates that the KIT SP inhibitors, DP-2976 and DP-4851, 
effectively inhibit the KIT D816V activating mutation and offer a novel mechanism to 
inhibit neoplastic mast cell proliferation and mast cell activation.
The inability of high ATP concentrations (4 mM) to blunt the inhibitory potencies of 
DP-2976 and DP-4851 further demonstrated that these KIT SP inhibitors function through 
an ATP-independent mechanism of action. Additionally, whereas ATP binding pockets are 
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highly conserved throughout the kinome, switch pockets possess greater structural diversity. 
As a result, compounds targeting the switch pocket may inhibit kinase activity with higher 
selectivity. Indeed, the KIT SP inhibitors, DP-2976 and DP-4851, both displayed low 
nanomolar IC50 values in WT and KIT D816V kinase assays with modest off-target 
inhibition against other kinases (data not shown). Further, in our cell based assays, the KIT 
SP inhibitors displayed specific inhibition of KIT phosphorylation and KIT mediated (SCF) 
enhanced mast cell degranulation (Figures 2, 3, 6, 7).
The ATP-competitive kinase inhibitor which has demonstrated the most promise for 
advanced forms of systemic mastocytosis is PKC 412.(28, 29) PKC 412 is a multikinase 
inhibitor shown to not only inhibit neoplastic mast cell proliferation, but also antigen/IgE-
dependent mediator release in human blood basophils and mast cells.(23, 24) Both DP-2976 
and DP-4851 exhibited more potent inhibition profiles compared to PKC 412 in the HMC 
1.1 (KIT D816V negative) and HMC 1.2 (KIT D816V positive) neoplastic mast cell lines 
and induced similar levels of apoptosis (Figure 4). Ex vivo studies examining the effects of 
the KIT SP inhibitors on neoplastic mast cells from patients with KIT D816V systemic 
mastocytosis displayed significant levels of inhibition comparable to PKC 412 (Figure 5). 
Overall, DP-2976 and DP-4851 inhibited neoplastic mast cell proliferation and/or survival at 
a level similar to (if not greater) than PKC 412, which is currently in a phase II clinical trial 
for systemic mastocytosis.
As our molecular understanding of advanced forms of systemic mastocytosis evolves, it has 
become apparent that cooperating genetic events may account for the diverse phenotypes 
and variable therapeutic responses observed in the disease.(30–32) Therefore, a multi-
targeted therapeutic approach may be required.(33) Whether the KIT SP inhibitors produce a 
synergistic effect when used in combination with kinase inhibitors targeting the ATP 
binding site or KIT independent targets is an area of further investigation. The selectivity of 
the KIT SP inhibitors should be advantageous in a combinational therapeutic approach.
In summary, we have demonstrated that targeting the switch pocket of KIT offers a novel 
and selective method to effectively suppress KIT D816V neoplastic proliferation and SCF 
enhanced mast cell activation. Our studies provide a strong rationale for further clinical 
development of KIT SP inhibitors for mastocytosis and other KIT driven disorders.
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Figure 1. KIT SP inhibitors suppress WT and mutant KIT kinase activity at nanomolar 
concentrations via an ATP independent mechanism
A. WT and mutant KIT kinase activity was measured in the presence of KIT SP inhibitors 
using the PK/LDH system. B. WT KIT kinase activity was measured in the presence of KIT 
SP inhibitors with varying concentrations (0.2, 1.2 or 4 mM) of ATP added to the reaction. 
IC50’s were calculated using the mean results of three separate experiments as shown for 
DP-2976 and DP-4851.
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Figure 2. KIT SP inhibitors suppress KIT autophosphorylation in transfected 293T cells
KIT and KIT D816V open reading frames were cloned into the pCDNA3.1 expression vector 
and transfected into 293T cells. The transfected cells were incubated with the KIT SP 
inhibitors (1 – 1000 nM, 0.1% DMSO) for 24 h. The cells were lysed and used for 
immunoblot analysis. The blots are representative of three separate experiments. The graphs 
were generated by scanning the blots of the three separate experiments and then normalizing 
to the SCF untreated condition. Data are presented as means ± SEM.
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Figure 3. KIT SP inhibitors suppress KIT autophosphorylation in HMC-1 mast cell lines
HMC 1.1 and HMC 1.2 cells were incubated for 3 h in Iscove’s DMEM media without FBS. 
The cells were washed 3 times in HEPES buffer containing 0.04% BSA. Three hundred 
thousand cells in 100 µl were then pre-incubated with the inhibitors (1 – 1000 nM, 0.1% 
DMSO) for 90 min at 37°C and 20 µl of the cell lysate was used for immunoblot analysis. 
The blots are representative of three separate experiments.
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Figure 4. KIT SP inhibitors suppress proliferation of, and induce apoptosis in, HMC-1 mast cell 
lines
A. HMC 1.1 and B. HMC 1.2 cells were cultured in the presence of inhibitors (1 – 1000 nM, 
0.1% DMSO) for 72 h. A CyQuant cell proliferation assay was used to assess growth 
inhibition. Values represent the % viable cells as compared to untreated controls. The data 
are presented as means +/− SEM of three separate experiments each performed in triplicate. 
C. HMC 1.1 and D. HMC 1.2 cells were cultured in the presence of 1000 nM inhibitor. At 
various time points, the cells were double stained with annexin V-FITC and Sytox Green 
dye. Cells stained with annexin V were defined as apoptotic. Baseline values of annexin V 
positive cells in untreated cultures were subtracted from each treatment. The percent of 
apoptotic cells for each culture is plotted. The data are presented as the means ± SEM of 
three separate experiments, each performed in triplicate.
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Figure 5. KIT SP inhibitors decrease the survival of primary bone marrow mast cells from 
patients with systemic mastocytosis
Bone marrow mononuclear cells from patients with systemic mastocytosis A. without the 
KIT D816V mutation (n=1) or B. with the KIT D816V mutation (n=5) were isolated and 
incubated with the inhibitors (0, 100, 1000 nM in 0.1% DMSO) for 7 d in the presence of 
SCF (100 ng/ml). Mast cell numbers were assessed by flow cytometry and normalized to 
values in the absence of inhibitor. The data in B are presented as the mean ± SEM of results 
from five patients with KIT D816V systemic mastocytosis.
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Figure 6. KIT SP inhibitors suppress KIT phosphorylation in primary HuMCs
HuMCs were pre-incubated for 90 min with the inhibitors (1 – 1000 nM, 0.1% DMSO). The 
cells were then stimulated with SCF (10 ng/ml) for 2 min, lysed and proteins separated by 
gel electrophoresis for immunoblot analysis. The blots are representative of three separate 
experiments. The graphs were generated by scanning the blots of the three separate 
experiments and then normalizing to the untreated condition. The data are presented as the 
mean ± SEM.
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Figure 7. KIT SP inhibitors suppress SCF-enhanced degranulation of primary HuMCs
HuMCs were sensitized overnight and pre-incubated with inhibitors for 90 min. Cells were 
then stimulated with ○ Ag (1 ng/ml) or ● Ag (0.1 ng/ml) +SCF (10 ng/ml) for 30 min. 
Degranulation was determined as % release of β-hexosaminidase. The data are presented as 
the mean ± SEM of three separate experiments each performed in triplicate.
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